Navigation Links
ResMed Inc. Announces Record Financial Results For The Quarter Ended And Six Months Ended December 31, 2011
Date:1/26/2012

SAN DIEGO, Jan. 26, 2012 /PRNewswire/ --ResMed Inc. (NYSE: RMD) today announced record revenue and income for the quarter ended December 31, 2011.  Revenue for the quarter ended December 31, 2011 was $332.7 million, a 9% increase (also a 9% increase on a constant currency basis) over the quarter ended December 31, 2010.  For the quarter ended December 31, 2011, net income was $62.9 million, an increase of 8%, compared to the quarter ended December 31, 2010.  Diluted earnings per share for the quarter ended December 31, 2011 were $0.42, an increase of 14% compared to the quarter ended December 31, 2010.  

(Logo:  http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)

SG&A expenses were $100.6 million for the quarter ended December 31, 2011, an increase of $9.0 million, or 10% (a 9% increase on a constant currency basis) over the quarter ended December 31, 2010.  The increase in SG&A was primarily due to expenses necessary to support sales growth.  SG&A costs were 30% of revenue in the quarter ended December 31, 2011, compared to 30% in the quarter ended December 31, 2010.R&D expenses were $27.2 million for the quarter ended December 31, 2011, or 8% of revenue.  R&D expenses increased by 24% (a 21% increase on a constant currency basis) compared to the quarter ended December 31, 2010.  

The company amortized acquired intangibles of $3.7 million ($2.7 million, net of tax) during the quarter ended December 31, 2011.  Stock-based compensation costs incurred during the quarter ended December 31, 2011 of $7.4 million ($5.8 million, net of tax) consisted of expenses associated with stock options, restricted stock units, and our employee stock purchase plan.  

For the six months ended December 31, 2011, revenue was $647.5 m
'/>"/>

SOURCE ResMed Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ResMed Announces Change to Outside US Dial-in Number for Conference Call and Webcast to Discuss Second Quarter 2012 Results
2. ResMed Announces Conference Call and Webcast to Discuss Second Quarter 2012 Results
3. ResMed Inc. Announces Financial Results for the Quarter Ended September 30, 2011
4. ResMed Announces Conference Call and Webcast to Discuss First Quarter 2012 Results
5. ResMed Inc. to Present at Upcoming Conferences
6. CareFusion and ResMed Announce Distribution Agreement for U.S. Hospital Market
7. ResMed Announces Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year End 2011 Results
8. ResMed Announces Acquisition of BiancaMed
9. ResMed Announces New iPhone App
10. ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011
11. The Next Generation in Bilevel Therapy Now Available on ResMeds Award-Winning S9™ Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Spanien, September 2, 2014 ... Das auf dem ESC-Kongress 2014 präsentierte ... Behandlung und Behandlungsergebnisse von schlaganfallgefährdeten Patienten ... Die Daten der ... Patienten, einer innovativen und unabhängigen Forschungsinitiative ...
(Date:9/2/2014)... September 2, 2014 , ... 2014 provide insight into treatment and outcomes of ... practice --   Data from nearly ... in the FIELD-Atrial Fibrillation (GARFIELD-AF), an innovative, independent ... strategies for atrial fibrillation (AF) patients remain sub-optimal ...
(Date:9/2/2014)... , Sept. 2, 2014 Particle Sciences, the ... its investment in development and manufacturing capabilities with the ... Karl Mueller , Particle Sciences, Associate Director Clinical Production, ... adding clean room square footage, equipment and staff across ... The company now has over 6000ft 2 of ...
Breaking Medicine Technology:Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9Particle Sciences Expands Drug Eluting Device Capabilities and Overall Clinical Trial Manufacturing Resources 2
... , ... The Gamida Cell-Teva Joint Venture,(JV) announced today that the ... registration, Phase,III clinical trial of StemEx (called ExCell) and has recommended ... data analysis is,anticipated to take place during Q2 2010. StemEx is ...
... , Feb. 9 CareFusion Corp. (NYSE: ... from continuing operations for the three and six months ended ... during our second quarter and performed ahead of our expectations," said ... spending made modest improvements during the quarter and we continued to ...
Cached Medicine Technology:Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma 2Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma 3CareFusion Reports Second Quarter Results 2CareFusion Reports Second Quarter Results 3CareFusion Reports Second Quarter Results 4CareFusion Reports Second Quarter Results 5CareFusion Reports Second Quarter Results 6CareFusion Reports Second Quarter Results 7CareFusion Reports Second Quarter Results 8CareFusion Reports Second Quarter Results 9CareFusion Reports Second Quarter Results 10CareFusion Reports Second Quarter Results 11CareFusion Reports Second Quarter Results 12CareFusion Reports Second Quarter Results 13CareFusion Reports Second Quarter Results 14CareFusion Reports Second Quarter Results 15CareFusion Reports Second Quarter Results 16CareFusion Reports Second Quarter Results 17CareFusion Reports Second Quarter Results 18
(Date:9/2/2014)... State University biochemists have discovered a family of proteins ... aureus , a pathogenic bacterium that can cause more ... Geisbrecht, professor of biochemistry and molecular biophysics, and Kasra ... , which is the cause of increasing common staph ... Proceedings of the National Academy of Sciences , or ...
(Date:9/2/2014)... have made it clear that a mother,s eating habits ... a profound impact on her offspring and their propensity ... now, the mechanisms behind this phenomenon were unclear. According ... of The FASEB Journal F , scientists ... a mother,s diet and an offspring,s risk of future ...
(Date:9/2/2014)... Many people believe that marijuana is not addictive, but ... people are able to obtain and consume cannabis legally ... are less likely to perceive it as addictive or ... General Hospital,s Center for Addiction Medicine, said in a ... use can have significant consequences, and we know that ...
(Date:9/2/2014)... Malvern, PA (PRWEB) September 02, 2014 ... healthcare communications and education, is proud to announce the ... and clinical resource center designed for healthcare professionals who ... website offers practitioners comprehensive access to:, , ... , Dedicated topic centers for diabetes, oncology, ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Healthcare professionals ... and most complete oncology guidelines available at the point ... and the National Comprehensive Cancer Network® ... other evidence and guidelines in the content available from ... , NCCN, a not-for-profit alliance of 25 of the ...
Breaking Medicine News(10 mins):Health News:Biochemists find new treatment options for staph infections, inflammatory diseases 2Health News:How genes link a mother's diet to the risk of obesity in her offspring 2Health News:'Pot Addiction' May Be Real, Study Suggests 2Health News:HMP Communications Holdings, LLC, Acquires Nutrition411.com 2Health News:DynaMed™ to Utilize Information from the National Comprehensive Cancer Network® 2Health News:DynaMed™ to Utilize Information from the National Comprehensive Cancer Network® 3Health News:DynaMed™ to Utilize Information from the National Comprehensive Cancer Network® 4
... growth of cancer cells in lab study , THURSDAY, Nov. ... form of leukemia holds promise as a possible treatment for ... (Sprycel) is used to treat chronic myeloid leukemia. Researchers at ... drug limited the growth and invasive powers of ovarian cancer ...
... ... and his company, Nationwide Relocation Services, are enormous supporters of breast cancer ... lethal disease are growing by number, as both men and women are ... its power to assist in costumers, moves when coping with such difficult ...
... ... PDF conversion product line. PDF2Office® for iWork a new product to convert PDF to ... ... Recosoft Corporation the developer of the PDF2Office® family of products, PDF2ID® tool for InDesign®, ...
... ... are under even more pressure to perform during the swine flu ... large and small over the coming months. While some large businesses ... for their employees, many medium and smaller businesses are not protected. ...
... FREEHOLD, N.J., Nov. 11 Speedus Corp. (Nasdaq: SPDE ... Graham was appointed to the Company,s Board of Directors. , ... which he founded in 1988, and has been a General ... Crosshill Debt II, L.P. since 2004. Prior to these roles ...
... Forward thinking Mayor A.C. Wharton, sees Benefit in New ... Memphis Mayor, A.C. Wharton stands up for the outstanding ... hosted by University of Tennessee Health & Science Center on ... Madison in Room 305. The National Bipolar Foundation has been ...
Cached Medicine News:Health News:Leukemia Drug May Help Some Ovarian Cancer Patients 2Health News:Nationwide Relocation Services Support Breast Cancer Awareness 2Health News:Nationwide Relocation Services Support Breast Cancer Awareness 3Health News:PDF2Office for iWork -- New Utility to Convert PDF Files Directly to Native Keynote & Pages '08/'09 Formats Ships 2Health News:PDF2Office for iWork -- New Utility to Convert PDF Files Directly to Native Keynote & Pages '08/'09 Formats Ships 3Health News:How to Survive Recession and Swine Flu Outbreak in Your Employees 2Health News:Speedus Corp. Names Stephen X. Graham to Board of Directors 2Health News:Memphis Mayor Endorses National Bipolar Foundation 2
... PowerSuite holmium laser combines excellent cutting, ... virtually bloodless procedures. It is also ... gall bladder stones of all compositions, ... tool. Because its laser light is ...
... VersaPulse PowerSuite holmium laser combines excellent ... precise, virtually bloodless procedures. It is ... and gall bladder stones of all ... surgical tool. Because its laser light ...
... perfecting mini-invasive endoscopic methods for ensuring extremely ... considerable social impact. The use of these ... and represents a valid backup in cutting ... family of Nd:YAG lasers is growing, developing ...
... hair removal for all skin ... Used for leg and facial ... Offers a large spot sizes ... fast treatment. An optional ...
Medicine Products: